MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
23.08
+0.08
+0.35%
Opening 12:05 04/03 EDT
OPEN
22.24
PREV CLOSE
23.00
HIGH
23.14
LOW
22.00
VOLUME
704.38K
TURNOVER
0
52 WEEK HIGH
59.91
52 WEEK LOW
21.70
MARKET CAP
2.90B
P/E (TTM)
-14.4521
1D
5D
1M
3M
1Y
5Y
1D
Apellis Pharmaceuticals Price Target Raised to $31.00/Share From $30.00 by Scotiabank
Dow Jones · 22h ago
Apellis Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Dow Jones · 22h ago
Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $31
Benzinga · 22h ago
Needham healthcare analysts hold analyst/industry conference call
TipRanks · 1d ago
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
NASDAQ · 1d ago
Apellis price target raised to $31 from $30 at Scotiabank
TipRanks · 1d ago
Scotiabank Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
TipRanks · 1d ago
More
About APLS
More
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Recently
Symbol
Price
%Change

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.